Skip navigation

Signatera

Transforming the management of cancer with personalized testing

Signatera is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer, with broad utility for cancer management. This MRD assay is highly sensitive and personalized for each patient, to help inform important treatment decisions.

Knowing earlier matters

Each person’s cancer is as unique as their fingerprint. Signatera is a MRD blood test that is personalized to each patient’s set of tumor mutations and can identify earlier than traditional tools if cancer is still present. Knowing this information can help you have a more informed discussion with your doctor regarding your treatment journey.

SIG-patients-knowing-earlier

How Signatera helps patients through their treatment

Scanxiety is very real for many patients previously diagnosed with cancer. Living scan to scan creates anxiety and fearful thoughts: is the cancer coming back? Through shared decision making, many patients are working closely with their doctors to incorporate Signatera into their treatment plan to provide additional information needed for confident decision making and to provide patients peace of mind between scans. Patient anxiety may be alleviated by gaining a greater understanding of their progress and feel more informed on how they apporach their treatment options.

 

Listen to Brook Bell’s story, a young CRC patient, discuss her experience using Signatera

Signatera is validated in multiple cancer types

SGN_colorectal-cancer

I have colorectal cancer

If you have been diagnosed with colorectal cancer, learn more how to identify residual disease and detect relapse sooner with Signatera MRD testing

SGN_immunotherapy

I am on immunotherapy

If you are undergoing immunotherapy and want to know how the Signatera MRD test can help monitor the effectiveness of your treatment

SIG-patients-right

Is Signatera right for me?

If you have been diagnosed with cancer such as breast, ovarian, lung or melanoma and want to learn more how to identify residual disease and detect relapse sooner

Why Signatera?

Signatera is a blood MRD test used for cancer detection and surveillance. It is personalized for each patient. It is used for molecular residual disease assessment and for treatment response monitoring.
A doctor may order Signatera along with routine follow-up exams to determine whether:

  • There are signs of cancer remaining in the body
  • Treatment (e.g., chemotherapy, radiation) is working
  • The cancer is recurring

How Signatera Works: a personalized and tumor informed approach to MRD surveillance

SGN_BESPOKE_STEP 1

A one-time analysis of both blood and tissue determines your unique set of tumor mutations.

SGN_BESPOKE_STEP 2

The MRD test is custom-built and personalized just for you, using your own tumor tissue.

SGN_BESPOKE_STEP 3

Signatera MRD test detects small fragments of ctDNA each time it is ordered as part of your routine follow-up blood tests. Patients who are ctDNA positive by Signatera are more likely to relapse.

Understanding your Signatera test results

Your test results will either be positive or negative for the presence of tumor DNA in your blood. Your doctor will receive the test report and will be able to discuss your results and answer questions. These results provide additional insights and may help guide your treatment plan.
IMPORTANT: Negative ctDNA results may change over time. A negative MRD test result doesn’t guarantee that cancer will never be detected in the future. This is why ongoing monitoring with the Signatera test, as directed by your doctor, is recommended—for early detection of residual disease
Negative result
A negative result indicates that tumor DNA was not detected in your blood and that you are more likely to remain cancer-free if you were diagnosed with early stage cancer.
If you have metastatic cancer, a negative result may mean that your treatment was able to decrease the amount of cancer cells to undetectable levels, meaning the treatment has been effective.
Positive result
A positive result indicates that tumor DNA has been detected in your blood and means there is higher risk for your cancer returning if you were diagnosed with early-stage cancer. Your doctor may continue to monitor your ctDNA levels to assess your tumor’s response to treatment.

Is Signatera right for you?

We’re here to help you find out